Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 987Neoplasms 796Carcinoma, Non-Small-Cell Lung 763Prostatic Neoplasms 588Colorectal Neoplasms 484Lung Neoplasms 468Neoplasm Metastasis 413Multiple Myeloma 382Leukemia, Myeloid, Acute 377Ovarian Neoplasms 316Pancreatic Neoplasms 297Melanoma 278Squamous Cell Carcinoma of Head and Neck 258Recurrence 244Carcinoma, Hepatocellular 240Brain Neoplasms 226Glioblastoma 217Triple Negative Breast Neoplasms 204Carcinoma, Renal Cell 200Head and Neck Neoplasms 198Lymphoma 193Stomach Neoplasms 190Precursor Cell Lymphoblastic Leukemia-Lymphoma 189Sarcoma 172Glioma 171Uterine Cervical Neoplasms 169Lymphoma, Non-Hodgkin 169Endometrial Neoplasms 169Lymphoma, Large B-Cell, Diffuse 166Urinary Bladder Neoplasms 160

Interventions

sparsentan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Proteinuria × 90 days × Clear all
NCT07224776 2026-05-18

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Brigham and Women's Hospital

Phase 1 Not yet recruiting
20 enrolled

Neoplasms, Proteinuria

NCT07561957 2026-05-01

A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines

St. James's Hospital, Ireland

Phase NA Recruiting
80 enrolled
Genitourinary

Kidney Diseases, Nephrotic Syndrome, Proteinuria, Tuberous Sclerosis, Renal Insufficiency, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡